Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Downstream Bottlenecks: Are They Myth or Reality?
Throughput Isn’t Where It Should Be, and There Is Some Disagreement as to Why
- Like the story of the blind men describing an elephant, the answer to whether a downstream bioprocessing bottleneck exists is largely one of perception. “The situation is even worse than it was two years ago,” according to Uwe Gottschalk, Ph.D., vp of purification technology, a business unit of Sartorius ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.